Clearbridge Health Completes \$0.96M Share Placement; Share Count Surges to 2.17B

Clearbridge Health Limited, a Singapore-based healthcare company, has successfully completed the allotment and issuance of 309,500,000 new ordinary shares in the company’s capital. The shares, priced at S\$0.0031 each, were issued as part of the Proposed Placement, raising approximately S\$959,450 for the company. This development was announced on 10 January 2025.

Key Developments Shareholders Need to Know

• Increased Share Count: Following the completion of the Proposed Placement, Clearbridge Health’s total number of issued shares has risen significantly from 1,859,224,056 to 2,168,724,056. This represents a notable 16.65% increase in the company’s share capital.
• Subscription Shares Details: The new shares were issued free of any claims or encumbrances and will rank equally with the existing shares, except they will not be entitled to dividends or distributions with a record date prior to the issuance date.
• Listing and Trading: The new shares are expected to be listed and quoted on the Catalist board of the Singapore Exchange Securities Trading Limited (SGX-ST) on 14 January 2025. Trading is slated to commence at 9:00 a.m. on the same day.

Potential Implications for Shareholders

The Proposed Placement, which significantly increases Clearbridge Health’s issued share capital, could have implications for share value. While the additional capital injection may bolster the company’s balance sheet, the dilution effect from the increased share count could put downward pressure on share prices. Shareholders and potential investors are advised to monitor market activity closely as trading of the new shares begins.

Cautionary Note

Clearbridge Health has issued a cautionary statement advising shareholders and potential investors to exercise prudence when trading in or dealing with the company’s securities. Those uncertain about their next steps are encouraged to consult their stockbrokers, bank managers, solicitors, or other professional advisers.

Regulatory Review

This announcement was reviewed by the company’s sponsor, ZICO Capital Pte. Ltd., but it has not been examined or approved by the SGX-ST. As such, the SGX-ST assumes no responsibility for the contents of the announcement.

For further inquiries, shareholders may contact the Sponsor representative, Ms. Goh Mei Xian, at ZICO Capital Pte. Ltd., located at 77 Robinson Road, #06-03 Robinson 77, Singapore 068896. Telephone: (65) 6636 4201.

Disclaimer

This article is intended for informational purposes only and does not constitute financial advice. Investors are advised to conduct their own research or consult with a professional adviser before making any investment decisions.